NXTC vs OCGN

NextCure, Inc. vs Ocugen, Inc. — Valuation Comparison 2026

NXTC

Biotechnology
NextCure, Inc.
Quality
4.5
out of 10
Value Trap
24
SAFE
Price
$6.40
Last close
Models
7/13
Active
VS

OCGN

Biotechnology
Ocugen, Inc.
Quality
6.6
out of 10
Value Trap
26
LOW
Price
$1.41
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType NXTC Fair ValueNXTC Upside OCGN Fair ValueOCGN Upside
Bayesian DCF Intrinsic $3.41 -46.7% $0.40 -71.8%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $18.39 +187.4%
Dynamic NAV Asset-Based $27.17 +324.5% $0.22 -84.3%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for NXTC vs OCGN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NXTC vs OCGN — Which Stock Is More Undervalued?

OCGN scores higher with a 6.6/10 quality rating vs NXTC's 4.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing NextCure, Inc. (NXTC) and Ocugen, Inc. (OCGN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NXTC currently trades at $6.40 with a QOC of 4.5/10, while OCGN trades at $1.41 with a QOC of 6.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).